Patents for A61P 35 - Antineoplastic agents (221,099)
02/2007
02/01/2007US20070026422 Vaccine-induced hepatitis B viral strain and uses thereof
02/01/2007US20070026389 Methods for drug discovery, disease treatment, and diagnosis using metabolomics
02/01/2007US20070026057 In vivo targeting of dendritic cells
02/01/2007US20070026007 treatment of conditions characterized by a need to modulate migratory-cell movement associated with specific sites in a subject; isolating a stromal-cell-derived fugetactic agent
02/01/2007US20070026001 APO-2 ligand-anti-her-2 antibody synergism
02/01/2007US20070026000 APO-2L receptor agonist and CPT-11 synergism
02/01/2007US20070025999 Treatment with anti-vegf antibodies
02/01/2007US20070025998 Methods for enhancing the efficacy of cancer therapy
02/01/2007US20070025996 Oculospanin as a tumor specific antigen and methods and compositions utilizing same
02/01/2007US20070025993 Tek antagonists
02/01/2007US20070025971 Substances causing differentiation
02/01/2007US20070025968 Methods for selecting and producing T cell peptide epitopes and vaccines incorporating said selected epitopes
02/01/2007US20070025961 Composition for stabilizing survival of transplanted hematopoietic stem cell, kit for obtaining the composition, method of stabilizing survival of transplanted hematopoietic stem cell, human monoclonal antibody or human polyclonal antibody and method of producing the same, gene encoding human monoclonal antibody and transf
02/01/2007US20070025959 Adjuvant combination formulations
02/01/2007US20070025913 Immunoglobulin which specifically binds endothelial cell-specific polypeptides; for use as evaluative tool in immunodiagnostic and drug efficacy studies
02/01/2007DE112005000612T5 Zusammensetzung zur Stabilisierung von Epigallocatechingallat (EGCG) in Wasserphase und Herstellungsverfahren davon Stabilization composition of epigallocatechin gallate (EGCG) in water phase and manufacturing method thereof
02/01/2007DE102005035568A1 Frizzled 9 als Biomarker für Substrukturen des humanen Gehirns Frizzled 9 as a biomarker for substructures of the human brain
02/01/2007CA2657886A1 Stem cell markers
02/01/2007CA2616790A1 Aqueous solution preparation containing camptothecin compounds
02/01/2007CA2616607A1 Therapeutic protocols using hyaluronan
02/01/2007CA2616534A1 Antitumor agent comprising 6'-amidino-2'-naphthyl4- guanidinobenzoate or salt thereof
02/01/2007CA2616395A1 B-cell reduction using cd37-specific and cd20-specific binding molecules
02/01/2007CA2616099A1 Novel anti-igf-ir antibodies and uses thereof
02/01/2007CA2616004A1 Use of truncated cysteine il28 and il29 mutants to treat cancers and autoimmune disorders
02/01/2007CA2615946A1 Pyrazolo pyrimidines useful as aurora kinase inhibitors
02/01/2007CA2615710A1 Sensitization of immune system against haptenized melanoma antigens
02/01/2007CA2615615A1 Anti-cd26 antibodies and methods of use thereof
02/01/2007CA2614919A1 1, 2, 3 -triazoles inhibitors of tubulin polymerization for the treatment of proliferative disorders
02/01/2007CA2608733A1 Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors
01/2007
01/31/2007EP1748075A1 Recombinant chemokine-antigen vaccine
01/31/2007EP1748070A1 Therapeutic medicine containing monoclonal antibody against folate receptor beta (fr-beta)
01/31/2007EP1748048A1 Imidazopyridine compound
01/31/2007EP1748046A2 Inhibitors of histone deacetylase
01/31/2007EP1747784A1 Target gene mimitin of myc
01/31/2007EP1747777A1 Medicinal agent
01/31/2007EP1747214A2 Dihydrobenzothiophenes
01/31/2007EP1747021A2 Self-immolative linkers and drug conjugates
01/31/2007EP1747020A2 7-t-butoxyiminomethylcamptothecin conjugated in position 20 with integrin antagonists
01/31/2007EP1747019A2 Camptothecin derivatives conjugated in position 20 with integrin antagonists
01/31/2007EP1746999A1 4-phenylamino-quinazolin-6-yl-amides
01/31/2007EP1746987A2 Dna pkinase inhibitors for treating cancer and diabetes
01/31/2007EP1478357B1 Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents
01/31/2007EP1034000B1 Method for obtaining vaccines for preventing the pathogenic effects related to a retroviral hiv infection
01/31/2007CN1906203A Glycosaminoglycan (GAG) mimetics
01/31/2007CN1906188A Phenyl-[4-(3-phenyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amine derivatives as IGF-1R inhibitors
01/31/2007CN1906183A N-acylsulfonamide apoptosis promoters
01/31/2007CN1906167A Novel pyridine derivative and pyrimidine derivative (2)
01/31/2007CN1906166A Novel pyridine derivative and pyrimidine derivative (1)
01/31/2007CN1905897A Antagonist anti-CD40 monoclonal antibodies and methods for their use
01/31/2007CN1905895A Biomarkers for the efficacy of somatostatin analogue treatment
01/31/2007CN1905864A DNA damage repair inhibitors for treatment of cancer
01/31/2007CN1904900A Human autogenous siRNA sequence, its application and screening method
01/31/2007CN1904059A Production method of konjak mannose using cellulase
01/31/2007CN1904058A Fermentation substrate of antitumour compound interseat shell lactone
01/31/2007CN1904057A Fermentation substrate of antitumour compound fungus epoxydiester
01/31/2007CN1904056A Recombinant adeno-associated virus comprising VEGFR Truncated Soluble cDNA and gene therapeutic agent comprising the same
01/31/2007CN1904055A Targeted liposome gene delivery
01/31/2007CN1904041A Human recombination phospholipase D2, its preparation method and application in preparation medicine
01/31/2007CN1903881A Antitumour multitarget composite antigen, its coding gene and application
01/31/2007CN1903880A Antitumour vascular endothelial growth factor VEGF-E antigen, its coding gene and application
01/31/2007CN1903877A Antitumour vascular endothelial growth factor receptor VEGF-R antigen and its coding gene and application
01/31/2007CN1903876A Polypeptide, nucleic acid molecule coding it and use
01/31/2007CN1903875A Antitumour integrator alpha V beta 3 antigen and its coding gene and application
01/31/2007CN1903864A Bisulfonate radical substituted 1,2-diphenyl ethylene diamine platinum compound and its preparation
01/31/2007CN1903374A Application of colon bacillus for preparing medicine for diagnosis and treatment of tumor
01/31/2007CN1903373A Application of expression TRAIL protein colon bacillus for preparing medicine to treat tumor
01/31/2007CN1903366A Targeted nanometer medicine carrier and its prepn. method
01/31/2007CN1903359A Application of musculus growth inhibin for preparing anticarcinogen
01/31/2007CN1903346A Traditional Chinese medicine for treating gastric carcinoma
01/31/2007CN1903341A Quick-acting specific medicine for treating benign encephaloma
01/31/2007CN1903340A Extractive of bullbrier genus plants, prepn. method and application thereof
01/31/2007CN1903308A Active position of Omithogalum caudatum Ait its prepn. method, medicine and application thereof
01/31/2007CN1903274A Medicine for treating precancer
01/31/2007CN1903264A Method for testing and controlling quality of Zengkangning prepn.
01/31/2007CN1903228A Prepn. of self-emulsion of glossy ganoderma spore oil, and its prepn. method
01/31/2007CN1903201A Injection prepn. contg. 10-hydroxy-9-allyl-camptothecine, and its prepn. method
01/31/2007CN1903196A Gliclazide dripping pills for treating diabetes
01/31/2007CN1297636C Fuel additive
01/31/2007CN1297567C Double functional fusion protein possessing antineoplastic functions, method for making same and use thereof
01/31/2007CN1297566C DNA for encoding the RGI polypeptide
01/31/2007CN1297556C New benzo[b]chromeno-naphthyridin-7-one and pyrano[2',3':7,8] quino[2,3-b]quinoxalin-7-one compounds, process for their preparation and pharmaceutical compositions containing them
01/31/2007CN1297554C Amido ether substituted imidazoquinolines
01/31/2007CN1297318C Prepn of core-shell type nano compound hydroxyapatiti-liposome particle
01/31/2007CN1297316C Mutant forms of cholera holotoxin as adjuvant
01/31/2007CN1297312C Recombinant phage vaccine of tumor proliferation related growth factor and its application
01/31/2007CN1297303C Tumor eliminating powder
01/31/2007CN1297297C Traditional Chinese medicine composition, its preparation method and application for preparing medicine to treat cancer
01/31/2007CN1297285C Becterin of Serratia marcescens for curing
01/31/2007CN1297281C Method for treatment of leukaemia
01/31/2007CN1297277C Laminaran granule and its preparation technology
01/31/2007CN1297269C Use of epothilone derivatives for the treatment of hyperparathyroidism
01/31/2007CN1297259C Total diterpene phenol originated from rosemary, its preparation method and use
01/30/2007US7169930 Analogs of epothilone
01/30/2007US7169929 Diaryl 1,2,4-triazole derivatives as a highly selective cyclooxygenase-2 inhibitor
01/30/2007US7169925 Indole derivatives as interleukin-4 gene expression inhibitors
01/30/2007US7169905 Modified peptides as therapeutic agents
01/30/2007US7169819 A pharmaceutical formulation for parenteral delivery, comprising a retinide such as fenretinide in combination with a solvent (an alcohol) and a alkoxylate castor oil, capable of dispersing or dissolving the retinide; anticancer agent
01/30/2007US7169817 Treatment and/or prevention of diseases or disorders mediated by lymphocyte interactions.
01/30/2007US7169814 Guanidinium transport reagents and conjugates
01/30/2007US7169813 metabolite of fenretinide; 4-oxo-N-(4-hydroxyphenyl) retinamide (4-oxo-4-HPR); antiproliferative; antitumor; ovarian carcinoma, breast tumor, neuroblastoma; overcomes 4-HPR resistance